COLUMVI (glofitamab-gxbm) is a bispecific CD20-directed CD3 T-cell engager. COLUMVI (glofitamab-gxbm) injection is a sterile, preservative-free, colorless, clear solution supplied in single-dose vials for intravenous infusion.COLUMVI is supplied in 2.5 mg/2.5 mL and 10 mg/10 mL single-dose vials at a concentration of 1 mg/mL. Each mL of solution contains 1 mg glofitamab-gxbm, histidine (0.63 mg), histidine hydrochloride monohydrate (3.34 mg), methionine (1.49 mg), polysorbate 20 (0.5 mg), sucrose (82.15 mg), and Water for Injection, USP, at pH 5.5.
COLUMVI (glofitamab-gxbm) Injection- 2.5 mg/2.5 mL (1 mg/mL) in a single-dose vial. 10 mg/10 mL (1 mg/mL) in a single-dose vial.
Please click here- https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761309s000lbl.pdf
COLUMVI (glofitamab-gxbm) is a bispecific CD20-directed CD3 T-cell engager indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) or large B-cell lymphoma (LBCL) arising from follicular lymphoma, after two or more lines of systemic therapy.